BriaCell Therapeutics (TSX:BCT) EV-to-EBIT : -1.14 (As of Apr. 26, 2024)

BriaCell Therapeutics EV-to-EBIT Chart

BriaCell Therapeutics Annual Data
	Trend	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23
EV-to-EBIT		Get a 7-Day Free Trial					-2.11	-1.38	-1.53	-2.22	-4.17

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBIT	Get a 7-Day Free Trial															-4.11	-5.67	-4.17	-2.74	-2.35

Competitive Comparison of BriaCell Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, BriaCell Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's EV-to-EBIT falls into.

BriaCell Therapeutics EV-to-EBIT Calculation

BriaCell Therapeutics's EV-to-EBIT for today is calculated as:

BriaCell Therapeutics's current Enterprise Value is C$39.54 Mil.
BriaCell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-34.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics  (TSX:BCT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BriaCell Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

BriaCell Therapeutics's Enterprise Value for the quarter that ended in Jan. 2024 was C$81.59 Mil.
BriaCell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-34.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description